250 related articles for article (PubMed ID: 9361572)
21. Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Harenberg J; Riess H; Büller HR; Brom J; Weidinger G; Huisman MV
Haematologica; 2003 Oct; 88(10):1157-62. PubMed ID: 14555312
[TBL] [Abstract][Full Text] [Related]
22. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
[TBL] [Abstract][Full Text] [Related]
23. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
[TBL] [Abstract][Full Text] [Related]
24. [Conventional or low molecular weight heparin in the treatment of venous thromboembolic disease?].
Ruiz Manzano J; Monreal M
Med Clin (Barc); 1998 Nov; 111(18):697-9. PubMed ID: 9887434
[No Abstract] [Full Text] [Related]
25. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis.
Hull R; Delmore T; Carter C; Hirsh J; Genton E; Gent M; Turpie G; McLaughlin D
N Engl J Med; 1982 Jan; 306(4):189-94. PubMed ID: 7033782
[TBL] [Abstract][Full Text] [Related]
26. Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin.
Kovacs MJ; Kearon C; Rodger M; Anderson DR; Turpie AG; Bates SM; Desjardins L; Douketis J; Kahn SR; Solymoss S; Wells PS
Circulation; 2004 Sep; 110(12):1658-63. PubMed ID: 15364803
[TBL] [Abstract][Full Text] [Related]
27. Treatment of established deep vein thrombosis: a review of the therapeutic armamentarium.
Berkowitz SD
Orthopedics; 1995 Jul; 18 Suppl():18-20. PubMed ID: 7479421
[TBL] [Abstract][Full Text] [Related]
28. [Drug therapy of deep venous thrombosis].
Bounameaux H
Ther Umsch; 1996 Apr; 53(4):272-6. PubMed ID: 8658349
[TBL] [Abstract][Full Text] [Related]
29. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin.
Anand S; Ginsberg JS; Kearon C; Gent M; Hirsh J
Arch Intern Med; 1996 Aug 12-26; 156(15):1677-81. PubMed ID: 8694666
[TBL] [Abstract][Full Text] [Related]
30. Therapy of acute thromboembolism with heparin and warfarin.
Carter BL
Clin Pharm; 1991 Jul; 10(7):503-18. PubMed ID: 1860301
[TBL] [Abstract][Full Text] [Related]
31. The treatment of venous thromboembolism.
Hirsh J
Nouv Rev Fr Hematol (1978); 1988; 30(3):149-53. PubMed ID: 3047668
[TBL] [Abstract][Full Text] [Related]
32. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis.
Hull R; Hirsh J; Jay R; Carter C; England C; Gent M; Turpie AG; McLoughlin D; Dodd P; Thomas M; Raskob G; Ockelford P
N Engl J Med; 1982 Dec; 307(27):1676-81. PubMed ID: 6755255
[TBL] [Abstract][Full Text] [Related]
33. Anticoagulant therapy for acute venous thromboembolism: what we think we know and what the data show for the timing of recurrent events.
Stein PD; Hull RD; Matta F; Yaekoub AY
Clin Appl Thromb Hemost; 2009 Dec; 15(6):609-12. PubMed ID: 19825911
[TBL] [Abstract][Full Text] [Related]
34. [Health care economics evaluation of inpatient treatment of venous thrombosis with unfractionated heparin versus subcutaneous low molecular weight heparin at home].
Osterkorn D; Schramm W; Szucs T
Med Klin (Munich); 1996 Sep; 91(9):607-9. PubMed ID: 8984321
[TBL] [Abstract][Full Text] [Related]
35. [Therapy of thromboses with low molecular weight heparins].
Haas S
Z Kardiol; 1993; 82 Suppl 2():77-80. PubMed ID: 8392238
[TBL] [Abstract][Full Text] [Related]
36. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects.
Hull RD; Pineo GF; Raskob GE
Haemostasis; 1998; 28 Suppl 3():8-16. PubMed ID: 10069757
[TBL] [Abstract][Full Text] [Related]
37. Established venous thromboembolism therapies: heparin, low molecular weight heparins, and vitamin K antagonists, with a discussion of heparin-induced thrombocytopenia.
Pendleton RC; Rodgers GM; Hull RD
Clin Chest Med; 2010 Dec; 31(4):691-706. PubMed ID: 21047576
[TBL] [Abstract][Full Text] [Related]
38. Continuous intravenous heparin infusion prevents peri-operative thromboembolic events in bariatric surgery patients.
Quebbemann B; Akhondzadeh M; Dallal R
Obes Surg; 2005 Oct; 15(9):1221-4. PubMed ID: 16273676
[TBL] [Abstract][Full Text] [Related]
39. Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group.
Hull RD; Raskob GE; Brant RF; Pineo GF; Elliott G; Stein PD; Gottschalk A; Valentine KA; Mah AF
Arch Intern Med; 2000 Jan; 160(2):229-36. PubMed ID: 10647762
[TBL] [Abstract][Full Text] [Related]
40. [Cancer, thromboembolia and antithrombotic therapy: is there an anticoagulant of choice?].
Scharf RE
Dtsch Med Wochenschr; 2011 Nov; 136(47):2403. PubMed ID: 22094968
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
